Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
1.860
-0.010 (-0.53%)
At close: Nov 4, 2024, 4:00 PM
1.900
+0.040 (2.15%)
Pre-market: Nov 5, 2024, 8:35 AM EST
Immuneering Employees
Immuneering had 68 employees as of December 31, 2023. The number of employees decreased by 5 or -6.85% compared to the previous year.
Employees
68
Change (1Y)
-5
Growth (1Y)
-6.85%
Revenue / Employee
n/a
Profits / Employee
-$824,507
Market Cap
55.16M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Dec 31, 2021 | 64 | 38 | 146.15% |
| Dec 31, 2020 | 26 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Qilian International Holding Group | 298 |
| Singular Genomics Systems | 255 |
| Vor Biopharma | 168 |
| VolitionRx | 110 |
| Theratechnologies | 103 |
| Shattuck Labs | 75 |
| Actinium Pharmaceuticals | 49 |
| Protara Therapeutics | 27 |
IMRX News
- 7 weeks ago - Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - GlobeNewsWire
- 3 months ago - Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer - GlobeNewsWire
- 5 months ago - Immuneering to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 months ago - Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 months ago - Immuneering Recognizes Melanoma Awareness Month - GlobeNewsWire
- 7 months ago - IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models - GlobeNewsWire
- 7 months ago - Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire